Tetra Bio Pharma (TBPMQ) Stock Price
Tetra Bio Pharma Price
Tetra Bio Pharma stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Tetra Bio Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Tetra Bio Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Tetra Bio Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Tetra Bio Pharma Price |
|---|---|
| 6/21/2026 | 0.00 CAD |
| 6/7/2026 | 0.00 CAD |
| 6/5/2026 | 0.00 CAD |
| 6/2/2026 | 0.00 CAD |
| 5/27/2026 | 0.00 CAD |
| 4/30/2026 | 0.00 CAD |
Tetra Bio Pharma Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Tetra Bio Pharma Income Statement, Balance Sheet, Cash Flow Statement
| EBITM CAD |
|---|
| NET INCOMEM CAD |
| NET INCOME GROWTH% |
| SHARESM |
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | -1.00 | -6.00 | – | -13.00 | -20.00 | -24.00 |
| – | -1.00 | – | – | – | – | -2.00 | – | – | – | -6.00 | – | -15.00 | -26.00 | -52.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 73.33 | 100.00 |
| 3.08 | 5.22 | 7.91 | 11.39 | 19.07 | 23.94 | 26.25 | 28.52 | 55.47 | 64.81 | 107.80 | 107.80 | 107.80 | 107.80 | 107.80 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Tetra Bio Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Tetra Bio Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Tetra Bio Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Tetra Bio Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Tetra Bio Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Tetra Bio Pharma stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Tetra Bio Pharma Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Tetra Bio Pharma business model & stock analysis
Tetra Bio Pharma SWOT Analysis
Strengths
Tetra Bio Pharma Inc has a robust R&D department, which allows them to constantly innovate and develop new pharmaceutical products.
The company offers a wide range of pharmaceutical products, catering to different medical conditions and patient needs. This diversity increases their market share and revenue potential.
Tetra Bio Pharma Inc has established strategic partnerships with other pharmaceutical companies, which enables them to access new markets, share resources, and strengthen their overall position in the industry.
Weaknesses
The company relies heavily on external funding for their research initiatives. Any fluctuations or discontinuation of funding sources may impact their ability to conduct research and develop new products.
As of now, Tetra Bio Pharma Inc has a relatively limited global presence, mainly focusing on specific geographic regions. This restricts their market reach and potential for growth.
Opportunities
With the growing acceptance of medical cannabis as a treatment option, Tetra Bio Pharma Inc can capitalize on this opportunity and expand their product offerings in this segment.
The company can explore and enter emerging markets, where there is a growing demand for pharmaceutical products. This would allow them to tap into new customer bases and diversify their revenue streams.
Threats
The pharmaceutical industry is highly competitive, with numerous players vying for market share. Tetra Bio Pharma Inc faces significant competition from both established companies and emerging startups.
The strict regulatory environment surrounding pharmaceutical products poses a challenge for Tetra Bio Pharma Inc. Any changes in regulations or failure to comply with existing regulations can impact their business operations.
Tetra Bio Pharma Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Tetra Bio Pharma historical P/E ratio, EBIT multiple, and P/S ratio
Tetra Bio Pharma annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Tetra Bio Pharma shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Tetra Bio Pharma stock splits
Tetra Bio Pharma shareholder structure
| % | Name |
|---|---|
0.99421% | |
0.00000% | |
0.00000% | |
0.00000% | |
0.00000% | |
0.00000% |
Tetra Bio Pharma Executives and Management Board
11 members · avg. age 64 · 55 % women
Dr. Guy Chamberland
Chief Executive Officer, Director, Chief Regulatory Officer · since 2016
436,642.00 CAD
Management
Mr. Steeve Neron
Chief Commercial Officer
Ms. Leslie Auld
Chief Financial Officer
Dr. Graham Wood
Chief Operating Officer
Ms. Dania Scott
Senior Vice President - Commercial Strategy
Dr. Melanie Kelly
Chief Scientific Officer
Board of Directors
Dr. Brent Norton (61)
Independent Chairman of the Board
Ms. Dale Weil (66)
Independent Director
Ms. Catherine Auld
Independent Director
Mr. John Kim
Independent Director
Ms. Natalie Leroux
Director · since 2021
Frequently asked questions about Tetra Bio Pharma
The business model of Tetra Bio Pharma Inc is focused on the development and commercialization of cannabinoid-based pharmaceutical products. As a biopharmaceutical company, Tetra Bio Pharma specializes in conducting clinical trials and obtaining regulatory approvals for its drug candidates. By leveraging the therapeutic potential of cannabinoids, Tetra Bio Pharma aims to address unmet medical needs and improve patients' quality of life. The company's portfolio includes products for various indications, such as pain management, oncology supportive care, and ophthalmology. Through strategic partnerships and its expertise in the pharmaceutical industry, Tetra Bio Pharma aims to bring innovative cannabinoid-based treatments to market, benefiting both patients and shareholders.
Tetra Bio Pharma Inc is primarily active in the pharmaceutical industry.
The main competitors of Tetra Bio Pharma Inc in the market include pharmaceutical companies such as GW Pharmaceuticals, Zynerba Pharmaceuticals, and Insys Therapeutics.
Tetra Bio Pharma Inc is a pharmaceutical company focused on developing bioactive cannabis-based medicines. Founded in 2007, Tetra Bio Pharma has a solid history of research and innovation in the field of medicinal cannabis. The company is dedicated to advancing the science behind cannabis and its potential therapeutic applications. With a team of experienced researchers and healthcare professionals, Tetra Bio Pharma aims to develop safe and effective pharmaceutical products to address unmet medical needs. As a leading player in the industry, Tetra Bio Pharma is committed to delivering high-quality cannabis-based treatments for patients in need.
Tetra Bio Pharma Inc has achieved several significant milestones in its journey. These include the successful completion of a Phase 2 clinical trial for its lead drug candidate, PPP001, in the treatment of chronic pain. The company also received approval for its Investigational New Drug (IND) application from the U.S. FDA, allowing it to conduct further clinical studies. Tetra Bio Pharma Inc has strengthened its position through strategic partnerships, such as the collaboration with IntelGenx to develop a pharmaceutical cannabis-based product. These achievements demonstrate Tetra Bio Pharma Inc's commitment to advancing innovative therapeutic solutions and establishing a strong presence in the pharmaceutical industry.
Tetra Bio Pharma Inc is primarily present in Canada and the United States.
Tetra Bio Pharma Inc represents a commitment to innovation, integrity, and excellence in the pharmaceutical industry. As a leading company, Tetra Bio Pharma Inc focuses on developing advanced cannabinoid-based treatments for various medical conditions. By harnessing the potential of cannabinoids and driving scientific research, the company aims to provide effective and safe therapies to improve patients' quality of life. Tetra Bio Pharma Inc prioritizes patient well-being and strives to maintain the highest ethical standards while delivering valuable healthcare solutions. Its dedication to scientific advancements and patient-centric approaches solidifies Tetra Bio Pharma Inc's position as a respected and trusted player in the pharmaceutical market.
9 analysts currently rate the Tetra Bio Pharma stock: 8 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Tetra Bio Pharma share trades at 0.00 EUR (0.00 CAD).
The Tetra Bio Pharma share (TBPMQ) is listed on 2 stock exchanges, including: Frankfurt (JAM1.F), Toronto (TBP.TO).
Tetra Bio-Pharma Inc. is a Canadian company specializing in the research and development of medical cannabis-based therapies. Its business model is based on providing safe, effective, and well-tolerated medications for pain relief, inflammation, and other symptoms. The company's portfolio includes both prescription and over-the-counter products, including a partnership with American company Jupiter Research to expand the distribution of medical devices for inhaling cannabis products. Tetra Bio-Pharma's main production facility is located in Canada, where it holds a license to produce medical cannabis. It also has a partnership with a Danish company named StenoCare to distribute its products in Europe. A significant part of Tetra Bio-Pharma's business model involves collaborating with scientific professionals and medical experts to ensure the safety, effectiveness, and high quality of its products. The company also has a research department focused on the clinical development of cannabinoid-based medications. One of Tetra Bio-Pharma's key areas is the development of pain relief medications. It has partnered with the Institute of Neuropsychopharmacology at Maastricht University to develop a medication called PPP001, which consists of a combination of THC and another cannabinoid called THCV. The medication is currently in Phase 2 of clinical trials. Another important product is the cannabinoid-based nasal spray called QIXLEEF, approved for pain and inflammation relief in advanced cancer patients. The nasal spray contains a combination of THC and CBD and is available in Canada and Europe. Overall, the company has developed a wide range of products and services tailored to the needs of patients and medical professionals seeking effective and safe treatment options. Through its diverse product portfolio, intensive research and development, as well as collaboration with medical experts and partners, Tetra Bio-Pharma has established a strong presence in the global medical cannabis market.
The revenue cannot currently be calculated for Tetra Bio Pharma.
The profit cannot currently be calculated for Tetra Bio Pharma.
The P/E ratio cannot be calculated for Tetra Bio Pharma at the moment.
The P/S cannot be calculated for Tetra Bio Pharma currently.
The Eulerpool Quality Score for Tetra Bio Pharma is 2/10.
The ISIN of Tetra Bio Pharma is CA88166Y1007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Tetra Bio Pharma is A2ASQ8. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Tetra Bio Pharma is TBPMQ. The ticker symbol is used to trade Tetra Bio Pharma shares on the stock exchange.
Tetra Bio Pharma paid dividends every year for the past 0 years.
Tetra Bio Pharma is assigned to the 'Health' sector.
The dividends of Tetra Bio Pharma are distributed in CAD.
Tetra Bio Pharma stock
Tetra Bio Pharma Peer Group
Tetra Bio Pharma Ticker
Tetra Bio Pharma FIGI
All fundamentals and in-depth analysis of Tetra Bio Pharma
Our stock analysis for Tetra Bio Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tetra Bio Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.